Generics overtake new drugs in EU centralised procedure
This article was originally published in Scrip
Executive Summary
One of the most striking statistics in the European Medicines Agency's first monthly report on the centralised approvals procedure is that generics have for the first time overtaken new products in terms of the number of applications for marketing authorisations dealt with by the agency. The report also reveals a sharp increase in the EMA's overall evaluation workload.
You may also be interested in...
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.